Insulin-like growth factor I: Pros and cons of a bioassay

Hormone Research in Paediatrics

Volumn 76, Issue SUPPL. 1, 2011, Pages 106-110

  Janssen, J A M J L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Insulin like growth factor I; Kinase receptor activation assay

Indexed keywords

DNA; GLUCOSE; GROWTH HORMONE; INSULIN; PEGVISOMANT; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR;

ACROMEGALY; BETA CHAIN; BIOASSAY; BLOOD GLUCOSE MONITORING; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; CONFERENCE PAPER; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HUMAN; IMMUNOASSAY; INSULIN LIKE GROWTH FACTOR 1 KINASE RECEPTOR ACTIVATION ASSAY; MICROTITER PLATE ASSAY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM;

AGED; AGED, 80 AND OVER; BIOLOGICAL ASSAY; CELL LINE; HUMANS; IMMUNOASSAY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1;

EID: 79960721447     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000329191     Document Type: Conference Paper

References (16)

1. Rajaram S, Baylink DJ, Mohan S: Insulinlike growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18: 801-831. (Pubitemid 28009568)
2. Collett-Solberg PF, Cohen P: The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am 1996; 25: 591-614. (Pubitemid 26304475)
3. Janssen JA, Lamberts SW: Is the measurement of free IGF-I more indicative than that of total IGF-I in the evaluation of the biological activity of the GH/IGF-I axis? J Endocrinol Invest 1999; 22: 313-315. (Pubitemid 29224333)
4. Janssen JA, van der Lely AJ, Lamberts SW: Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity. J Endocrinol Invest 2003; 26: 588-594. (Pubitemid 36998711)
5. Bidlingmaier M: Pitfalls of insulin-like growth factor I assays. Horm Res 2009; 71(suppl 1):30-33.
6. Clemmons DR: IGF-I assays: current assay methodologies and their limitations. Pituitary 2007; 10: 121-128. (Pubitemid 46863726)
7. Blum WF, Breier BH: Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1994; 4(suppl 1):11-19.
8. Frystyk J, Freda P, Clemmons DR: The current status of IGF-I assays - a 2009 update. Growth Horm IGF Res 2010; 20: 8-18.
9. Quarmby V, Quan C, Ling V, Compton P, Canova-Davis E: How much insulin-like growth factor I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy. J Clin Endocrinol Metab 1998; 83: 1211-1216. (Pubitemid 28496395)
10. Anckaert E, Schiettecatte J, Vanbesien J, Smitz J, Velkeniers B, De SJ: Variability among five different commercial IGF-1 immunoassays in conditions of childhood-onset GH deficiency and GH therapy. Acta Clin Belg 2006; 61: 335-339.
11. Sadick MD: Kinase receptor activation (KIRA): a rapid and accurate alternative to endpoint bioassays. Dev Biol Stand 1999; 97: 121-133.
12. Chen JW, Ledet T, Orskov H, Jessen N, Lund S, Whittaker J, De MP, Larsen MB, Christiansen JS, Frystyk J: A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab 2003; 284:E1149-E1155. (Pubitemid 36617461)
13. Brugts MP, Ranke MB, Hofland LJ, van der Wansem K, Weber K, Frystyk J, Lamberts SW, Janssen JA: Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. J Clin Endocrinol Metab 2008; 93: 2539-2545. (Pubitemid 352008517)
14. Brugts MP, van den Beld AW, Hofland LJ, van der Wansem K, van Koetsveld PM, Frystyk J, Lamberts SW, Janssen JA: Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. J Clin Endocrinol Metab 2008; 93: 2515-2522. (Pubitemid 352008515)
15. Moller L, Dalman L, Norrelund H, Billestrup N, Frystyk J, Moller N, Jorgensen JO: Impact of fasting on growth hormone signaling and action in muscle and fat. J Clin Endocrinol Metab 2009; 94: 965-972.
16. Beardsall K, Ogilvy-Stuart AL, Frystyk J, Chen JW, Thompson M, Ahluwalia J, Ong KK, Dunger DB: Early elective insulin therapy can reduce hyperglycemia and increase insulin-like growth factor-I levels in very low birth weight infants. J Pediatr 2007; 151: 611-617.